finance.yahoo.com ·
trisalus life sciences q1 earnings 020619092
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedTriSalus Life Sciences, a medical device company, reported a slight revenue decline and lowered guidance due to a commercial reorganization and FDA delay for its TriNav Advance device. The delay removes expected H2 2026 revenue from that product, but the company is expanding its sales force and has ongoing trials. Impact is company-specific, not sector-wide; commercial mechanism is weak near-term but may affect future growth trajectory.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $8.9M, down from $9.2M YoY
- 2026 revenue outlook revised to $54M-$57M
- FDA review for TriNav Advance delayed ~5 months
- No revenue contribution from TriNav Advance expected in H2 2026
- Sales force expansion and multiple active trials ongoing
TriSalus Life Sciences faces share price pressure down 2-5% within 48h due to FDA delay for TriNav Advance.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- MEDICAL_DEVICESmid
- MEDICAL_DEVICESshort